Form 4: MindMed CEO Robert Barrow Sells Shares to Cover Tax Obligations

MindMed's CEO, Robert Barrow, sold 19,106 common shares to cover tax obligations related to vested restricted stock units.

Summary

• Robert Barrow, the CEO of Mind Medicine (MindMed) Inc., sold 19,106 common shares on December 26, 2024.
• The sale was executed to satisfy withholding tax obligations related to the settlement of vested restricted stock units.
• The shares were sold under a Rule 10b5-1 plan adopted on June 15, 2022.
• The sale price ranged from $6.98 to $7.66, with a weighted average price of $7.43.
• Following the transaction, Mr. Barrow still beneficially owns 526,666 common shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any inside information.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are common across the industry.
• The use of a Rule 10b5-1 plan is a standard practice to avoid accusations of insider trading.
• The reported price range and weighted average price are typical for such transactions.

Stakeholder Impact

• The share sale has a minimal impact on shareholders as it is a small percentage of the total shares outstanding.
• The sale is a normal part of executive compensation and does not indicate any change in the company's outlook.

Key Dates

Keywords

MindMed, Robert Barrow, share sale, Form 4, insider trading, Rule 10b5-1, restricted stock units, tax obligations